dyskinesia

There are four attributes of a vertebral subluxation that contribute to brain-body ‘mismatching’.

In this podcast episode on tardive dyskinesia (TD), Joseph P. McEvoy, MD, interviews Leslie, a patient who was diagnosed with TD 10 years ago. She describes her journey to an accurate diagnosis, the impact that TD has on her daily life, and her advice for patients and providers affected by TD.

Presenters:

Joseph P. McEvoy MD
Professor
Psychiatry and Health Behavior
Psychiatrist
Augusta University
Augusta, Georgia

Leslie

This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.

For more programs in this series, visit:
https://bit.ly/3dUCVi6

In this first of 6 podcast episodes on tardive dyskinesia (TD), Drs Greg W. Mattingly and Jonathan M. Meyer have a discussion on identifying TD in clinical practice—including how to effectively screen patients during telehealth appointments. They cover who should be screened and how often, informal vs formal screening, and the valuable insight that family/caregiver reports can provide in the identification process. Additional conversation sheds light on differentiating TD from other movement disorders, including tics and tremors, and the role of primary care and other specialty providers in helping to identify TD. The experts round out the podcast with a focus on the impact of TD on both patient and caregiver quality of life—even mild TD can have an enormous influence over emotional, social, and mental well-being—bringing home the point that screening for and identifying TD early on is very important for patient outcomes.

Presenters:

Greg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

Jonathan M. Meyer, MD
Voluntary Clinical Professor
Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.

For more programs in this series, visit: 
https://bit.ly/3AhRXau

In this episode, Diana Perkins, MD, MPH, and Martha Sajatovic, MD, discuss the impact of tardive dyskinesia on social and functional domains and the benefits of proper assessment and treatment of tardive dyskinesia in improving patient quality of life in these areas.

Presenters:

Diana Perkins, MD, MPH
Professor of Psychiatry 
University of North Carolina School of Medicine
Chapel Hill, North Carolina 

Martha Sajatovic, MD
Professor of Psychiatry and Neurology
Departments of Psychiatry and Neurology
Case Western Reserve University School of Medicine
Cleveland, Ohio

Link to full program:
https://bit.ly/3GkJmUS

In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh, discuss who PCPs should screen for TD, adverse effects PCPs should put on their radar screen when monitoring patients on antipsychotics, how TD is different from parkinsonism, the use of anticholinergics, and which patients have an increased risk for TD when on antipsychotics.  

Presenters:

Greg Mattingly, MD
Associate Clinical Professor
Psychiatry, Psychopharmacology
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

W. Clay Jackson, MD, DipTh  
Assistant Professor of Clinical Family Medicine & Psychiatry
College of Medicine
University of Tennessee
Director
Palliative Care
West Cancer Center
Memphis, Tennessee

Link to full program:
https://bit.ly/2RM8hfM

In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh , discuss how the use of antipsychotics has changed in primary care patients, how primary care physicians can screen for tardive dyskinesia (TD), and increasing needs for the primary care physician in mental health.

Presenters:

Greg Mattingly, MD
Associate Clinical Professor
Psychiatry, Psychopharmacology
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

W. Clay Jackson, MD, DipTh  
Assistant Professor of Clinical Family Medicine & Psychiatry
College of Medicine
University of Tennessee
Director
Palliative Care
West Cancer Center
Memphis, Tennessee

Link to full program:
https://bit.ly/2RM8hfM

In this episode, John M. Kane, MD, and Rebecca S. Roma, MD, discuss clinical assessment of extrapyramidal symptoms (EPS), antiparkinsonian drugs, and tardive dyskinesia (TD). They review differentiating between TD and EPS, identify tools for diagnosing TD, and provide some important clinical pearls and evidence-based reasons for choosing different medications for treating EPS and TD.

Presenters:

John M. Kane, MD
Professor and Chairman
Department of Psychiatry
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Glen Oaks, New York

Rebecca S. Roma, MD
Medical Director
REACH, LLC
Pittsburgh, Pennsylvania

Link to full program:
https://bit.ly/2RM8hfM

In this episode, Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss clinical assessment and diagnosis of tardive dyskinesia (TD). They review using the AIMS exam for identification of dyskinesia in patients in both the clinical setting and via telepsychiatry. They also review how often to perform the AIMS exam, how to assess the results, and why it is important.

Presenters:
Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Joseph P. McEvoy, MD
Professor
Psychiatry and Health Behavior
Psychiatrist
Augusta University
Augusta, Georgia

Link to full program:
https://bit.ly/2RM8hfM

In this episode, Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss tardive dyskinesia (TD), mood disorders, and antipsychotics. They review current clinical considerations and assessments, including whether antipsychotic prescriptions for mood disorders have increased, if patients with mood disorder are at higher risk for TD and why, and when and how to use an AIMS exam, even in telepsychiatry. They also review the evidence base for VMAT2 inhibitors in TD, what nonevidence-based treatments healthcare professionals should avoid, and how to choose between the 2 VMAT2 inhibitors.  

Presenters:

Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Joseph Goldberg, MD
Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Content based on an online CME program supported by an educational grant from Neurocrine Biosciences.

Link to full program:
https://bit.ly/2RM8hfM